D. Hawkins

R. Ellenbogen, D. Hawkins, J. Zimmerman, 2008, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

G. Getz, M. Meyerson, James R. Anderson, 2014, Cancer discovery.

Efficacy of the MEK1/2 inhibitor trametinib in combination with clinically-investigated γ-secretase inhibitors in rhabdomyosarcoma

C. Keller, D. Hawkins, Megan M. Cleary, 2019, bioRxiv.

Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas

S. Steinberg, D. Hawkins, L. Helman, 2009, Clinical Cancer Research.

Survival of Tumor Megaprostheses Replacements about the Knee

S. Leopold, E. Conrad, D. Hawkins, 2006, Clinical orthopaedics and related research.

Clinical trial enrollment of adolescents and young adults with sarcoma

D. Reinke, G. Schwartz, R. Randall, 2017, Cancer.

Cost minimization analysis of two treatment regimens for low‐risk rhabdomyosarcoma in children: A report from the Children's Oncology Group

J. Meza, D. Hawkins, M. Okcu, 2014, Pediatric blood & cancer.

Shorter duration therapy that includes vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children's Oncology Group (COG).

J. Meza, A. Pappo, D. Hawkins, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.

James R. Anderson, S. Donaldson, C. Paidas, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Computed tomography in the evaluation of febrile neutropenic pediatric oncology patients.

D. Hawkins, J. Geyer, Julie R. Park, 2001, The Pediatric infectious disease journal.

Two boys with fragile x syndrome and hepatic tumors.

D. Hawkins, F. Tassone, R. Hagerman, 2008, Journal of pediatric hematology/oncology.

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low‐Risk Clinical Features: A Report From the Children's Oncology Group

James R. Anderson, J. Gastier-Foster, S. Skapek, 2016, Pediatric blood & cancer.

Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.

D. Hawkins, C. Arndt, J. Douglas, 2007, European journal of cancer.

Intensive Induction Chemotherapy and Delayed Irradiation in the Management of Parameningeal Rhabdomyosarcoma

D. Hawkins, J. Douglas, J. Felgenhauer, 2001, Journal of pediatric hematology/oncology.

Delayed primary excision with subsequent modification of radiotherapy dose for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

S. Donaldson, D. Rodeberg, C. Paidas, 2015, International journal of cancer.

Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

S. Donaldson, D. Rodeberg, D. Hawkins, 2019, International journal of radiation oncology, biology, physics.

Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.

James R. Anderson, S. Donaldson, D. Rodeberg, 2015, International journal of radiation oncology, biology, physics.

Automated Ascertainment of Typhlitis From the Electronic Health Record.

T. Lash, R. Gerbing, D. Hawkins, 2022, JCO clinical cancer informatics.

Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

D. Rodeberg, D. Hawkins, J. Breneman, 2020, International journal of cancer.

Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group.

S. Donaldson, R. Randall, D. Hawkins, 2011, International journal of radiation oncology, biology, physics.

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Jessica L. Davis, B. Tuch, A. Pappo, 2018, The Lancet. Oncology.

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, S. Donaldson, D. Rodeberg, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols‐III and ‐IV, 1984–1997: A report from the Children's Oncology Group

D. Rodeberg, D. Hawkins, L. Teot, 2013, Pediatric blood & cancer.

Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.

J. Meza, S. Donaldson, D. Rodeberg, 2012, International journal of radiation oncology, biology, physics.

Orofacial rhabdomyosarcoma in neonates and young children: a review of literature and management of four cases.

D. Hawkins, R. Chigurupati, D. Oda, 2002, Oral oncology.

Metastatic malignant melanoma presenting as pancytopenia in a three‐year‐old boy

R. Sze, D. Hawkins, V. Sybert, 2005, Pediatric blood & cancer.

Successful Dose-Intensive Treatment of Desmoplastic Small Round Cell Tumor in Three Children

D. Hawkins, J. Miser, P. Kurre, 2000, Journal of pediatric hematology/oncology.

Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas

D. Hawkins, T. Gooley, J. Douglas, 2002, Cancer.

Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups.

James R. Anderson, M. Stevens, D. Rodeberg, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, S. Skapek, D. Hawkins, 2015, Archives of pathology & laboratory medicine.

Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group.

A. Pappo, D. Hawkins, S. Qualman, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translating Discovery into Cures for Children with Cancer Childhood Cancer Research Landscape Report

Nancy F. Lenfestey, A. Jemal, K. Miller, 2016 .

Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies

D. Hawkins, S. Malempati, 2012, Pediatric blood & cancer.

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Funda Meric-Bernstam, Ryma Benayed, Marc Ladanyi, 2018, The New England journal of medicine.

The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

David M. Hyman, David S. Hong, Alberto S. Pappo, 2017 .

Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors

Jessica L. Davis, D. Hawkins, A. Al-Ibraheemi, 2019, The American journal of surgical pathology.

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

Jessica L. Davis, A. Pappo, D. Hawkins, 2018, Cancer.

Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.

Marcus R. Breese, R. West, J. Mora, 2014, The Journal of clinical investigation.

Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group

Angshumoy Roy, S. Spunt, S. Skapek, 2018, Clinical Cancer Research.

Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors

M. Hudson, J. Neglia, D. Hawkins, 2023, JACC. CardioOncology.

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

M. Sydes, P. Leavey, R. Goldsby, 2019, European journal of cancer.

Infantile NTRK-associated Mesenchymal Tumors

Jessica L. Davis, D. Hawkins, K. Tsuchiya, 2018, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

S. Spunt, S. Skapek, D. Hawkins, 2013, Pediatric blood & cancer.

High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.

J. Blay, U. Dirksen, A. Craft, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

K. S. Hall, M. Sydes, P. Leavey, 2016, The Lancet. Oncology.

Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse

S. Meshinchi, D. Hawkins, M. Loken, 2004, Pediatric blood & cancer.

Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study.

M. Hudson, L. Robison, J. Neglia, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group

James R. Anderson, S. Donaldson, D. Rodeberg, 2019, Cancer.

Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma

D. Hawkins, E. Rudzinski, R. Gorlick, 2015, Clinical Sarcoma Research.

Comparison of Genome-Wide Binding of MyoD in Normal Human Myogenic Cells and Rhabdomyosarcomas Identifies Regional and Local Suppression of Promyogenic Transcription Factors

Abraham P. Fong, Zizhen Yao, S. Tapscott, 2012, Molecular and Cellular Biology.

Clonality and Evolutionary History of Rhabdomyosarcoma

J. Khan, Jun S. Wei, M. Yohe, 2015, PLoS genetics.

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.

U. Dirksen, O. Delattre, A. Craft, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.

J. Eary, E. Conrad, S. Schuetze, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia

D. Hawkins, S. Borinstein, Min Xu, 2008, Pediatric blood & cancer.

Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group

E. Kleinerman, D. Hawkins, M. Bernstein, 2010, Clinical Cancer Research.

Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy

D. Hawkins, Carola A.S. Arndt, 2003, Cancer.

Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial

N. Ramirez, T. Alonzo, M. Mooney, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.

D. Hawkins, D. Friedman, J. Burns, 2003, Medical and pediatric oncology.

Spontaneous remission of congenital leukemia.

D. Hawkins, J. Dinulos, B. S. Clark, 1997, The Journal of pediatrics.

Patterns of PD‐1, PD‐L1, and PD‐L2 expression in pediatric solid tumors

T. Mcclanahan, E. Murphy, J. Yearley, 2017, Pediatric blood & cancer.

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force

J. Khan, C. Keller, P. Houghton, 2021, Journal of clinical medicine.

Title: Genome-Informed Targeted Therapy for Osteosarcoma Running title: Genome-Informed Targeted Therapy for Osteosarcoma

Krystal M. Straessler, Bogdan Tanasa, S. Spunt, 2018 .

Insights into pediatric rhabdomyosarcoma research: Challenges and goals

S. Tapscott, J. Khan, C. Antonescu, 2019, Pediatric blood & cancer.

Clinical Application of Prognostic Gene Expression Signature in Fusion Gene–Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group

James R. Anderson, M. Delorenzi, T. Triche, 2015, Clinical Cancer Research.

Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

James R. Anderson, J. Gastier-Foster, S. Skapek, 2013, American journal of clinical pathology.

A Novel Algorithm for Simpli fi cation of Complex Gene Classi fi ers in Cancer

James R. Anderson, T. Triche, J. Gastier-Foster, 2013 .

No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia.

D. Hawkins, B. Thomson, C. Koschmann, 2010, Archives of pediatrics & adolescent medicine.

Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion–negative rhabdomyosarcoma: A report from the Children's Oncology Group

Ling Lin, M. Ducar, A. Thorner, 2018, Cancer.

Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group

S. Donaldson, D. Rodeberg, D. Hawkins, 2022, Pediatric blood & cancer.

Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.

Jessica L. Davis, M. Rosen, R. Randall, 2020, The Lancet. Oncology.

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, D. Rodeberg, S. Spunt, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.

R. Randall, A. Ferrari, S. Spunt, 2019, European journal of cancer.

Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.

T. Alonzo, M. Mooney, D. Hawkins, 2021 .

Summary of COVID‐19 clinical practice adjustments across select institutions

M. Link, D. Hawkins, A. Kung, 2020, Pediatric Blood & Cancer.

Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups

C. Haie-meder, M. Stevens, D. Rodeberg, 2018, Pediatric blood & cancer.

Reduction of cyclophosphamide dose for patients with subset 2 low‐risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

James R. Anderson, J. Meza, A. Pappo, 2017, Cancer.

Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group

J. Meza, S. Donaldson, A. Pappo, 2011, Pediatric blood & cancer.

Myogenin, AP2&bgr;, NOS-1, and HMGA2 Are Surrogate Markers of Fusion Status in Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children’s Oncology Group

Stephen X Skapek, Julie M Gastier-Foster, James R. Anderson, 2014, The American journal of surgical pathology.

The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology Group.

James R. Anderson, D. Rodeberg, C. Paidas, 2008, Journal of pediatric surgery.

Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.

C. Bult, P. Meltzer, P. Sorensen, 2016, Cancer genetics.

The COVID‐19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP‐E, SIOP‐PODC, IPSO, PROS, CCI, and St Jude Global

P. Kearns, D. Hawkins, C. Rodríguez-Galindo, 2020, Pediatric Blood & Cancer.

High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

U. Dirksen, A. Craft, R. Goldsby, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.

James R. Anderson, D. Hawkins, W. Meyer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children’s Oncology Group

J. Gastier-Foster, J. LaBaer, S. Skapek, 2020, Scientific Reports.

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

James R. Anderson, S. Donaldson, D. Rodeberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors

G. Armstrong, M. Hudson, L. Robison, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium

Jun S. Wei, S. Sindiri, M. Yohe, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study

David W. Henry, James R. Anderson, S. Spunt, 2013, Pediatric blood & cancer.

Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma: A joint analysis from the European paediatric soft tissue sarcoma Study Group and the Children's Oncology Group.

R. Randall, A. Ferrari, S. Spunt, 2017, European journal of cancer.

Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc).

U. Dirksen, B. Morland, I. Judson, 2016 .

A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.

R. Randall, F. Laurie, A. Pappo, 2019, The Lancet. Oncology.

Survival after recurrence of Ewing's sarcoma family of tumors.

D. Hawkins, J. Sanders, T. Pendergrass, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma

A. Goldenberg, J. Khan, Jun S. Wei, 2021, JCO precision oncology.

Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report

P. Leavey, R. Randall, D. Hawkins, 2021, Journal of Clinical Oncology.

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma

James R. Anderson, D. Rodeberg, S. Spunt, 2018, Cancer.

Patterns of chemotherapy‐induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

James R. Anderson, D. Hawkins, A. Rosenberg, 2017, Pediatric blood & cancer.

Patterns of chemotherapy‐induced toxicities in younger children and adolescents with rhabdomyosarcoma

James R. Anderson, A. Pappo, S. Spunt, 2012, Cancer.

Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology Group.

James R. Anderson, S. Donaldson, D. Rodeberg, 2011, International journal of radiation oncology, biology, physics.

Sarcoma REGIONAL NODAL INVOLVEMENT AND PATTERNS OF SPREAD ALONG IN-TRANSIT PATHWAYS IN CHILDREN WITH RHABDOMYOSARCOMA OF THE EXTREMITY : A REPORT FROM THE CHILDREN ’ S ONCOLOGY GROUP

James R. Anderson, S. Donaldson, D. Rodeberg, 2011 .

Ewing sarcoma/primitive neuroectodermal tumor arising from the adrenal gland in an adolescent

D. Hawkins, K. Gow, Jacob T. Stephenson, 2011, Pediatric blood & cancer.

Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study.

C. Paidas, A. Pappo, D. Hawkins, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors Associated With Mortality in Pediatric vs Adult Nasopharyngeal Carcinoma.

D. Hawkins, E. Beierle, K. Gow, 2016, JAMA otolaryngology-- head & neck surgery.

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, D. Rodeberg, D. Hawkins, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early results from Children's Oncology Group (COG) ARST08P1: Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS).

James R. Anderson, D. Rodeberg, D. Hawkins, 2015 .

The Care of Children With Cancer During the COVID-19 Pandemic.

P. Kearns, D. Hawkins, S. Sands, 2021, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report

W. Curran, M. Schnall, M. Bertagnolli, 2020, Cancer.

Evaluation of chemotherapy response in pediatric bone sarcomas by [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography

J. Eary, E. Conrad, D. Hawkins, 2002, Cancer.

Topotecan by 21‐day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study

P. Adamson, D. Hawkins, J. Whitlock, 2006, Pediatric blood & cancer.

Patients with completely resected nongenitourinary low‐risk embryonal rhabdomyosarcoma are candidates for reduced duration low‐intensity chemotherapy

A. Ferrari, D. Hawkins, G. Seitz, 2022, Cancer.

Development of Curative Therapies for Ewing Sarcomas by Interdisciplinary Cooperative Groups in Europe

W. Winkelmann, N. Willich, C. Rübe, 2015, Klinische Pädiatrie.

IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy

Robin L. Jones, A. Ribas, R. Pierce, 2021, Journal for ImmunoTherapy of Cancer.

PAX‐FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

James R. Anderson, T. Triche, J. Gastier-Foster, 2013, Pediatric blood & cancer.

Comparison of Multidimensional Flow Cytometry With Standard Morphology for Evaluation of Early Marrow Response in Pediatric Acute Lymphoblastic Leukemia

J. Radich, W. Leisenring, S. Meshinchi, 2001, Journal of pediatric hematology/oncology.

[F‐18]‐fluorodeoxy‐D‐glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults

J. Eary, E. Conrad, S. Schuetze, 2009, Cancer.

Pegfilgrastim for prevention of chemotherapy‐associated neutropenia in pediatric patients with solid tumors

D. Hawkins, S. Borinstein, L. Winter, 2009, Pediatric blood & cancer.

Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

James R. Anderson, J. Meza, A. Pappo, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline Cancer-Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report from the Children's Oncology Group.

Michael M. Khayat, R. Gibbs, E. Boerwinkle, 2020, Journal of the National Cancer Institute.

MRI and CT of Low-Grade Fibromyxoid Sarcoma in Children: A Report From Children's Oncology Group Study ARST0332.

S. Spunt, D. Hawkins, D. Parham, 2015, AJR. American journal of roentgenology.

Investigating the heterogeneity of alkylating agents’ efficacy and toxicity between sexes: A systematic review and meta‐analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)

J.R. Anderson, U. Dirksen, J. Pignon, 2017, Pediatric blood & cancer.

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.

D. Hawkins, B. Widemann, T. Zwerdling, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy

J. Eary, E. Conrad, S. Schuetze, 2005, Cancer.

Assessing the scale of tumor heterogeneity by complete hierarchical segmentation of MRI

A. Trister, D. Hawkins, R. Ermoian, 2015, Physics in medicine and biology.

Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

B. Crompton, A. Thorner, C. Cibulskis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

Ha M Dang, D. Hawkins, M. Bernstein, 2021, Pediatric blood & cancer.

Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.

F. O’Sullivan, J. Eary, E. Conrad, 2014, The Journal of bone and joint surgery. American volume.

(F-18)-Fluorodeoxy-D-Glucose-

J. Eary, E. Conrad, S. Schuetze, 2009 .

Positron emission tomography in musculoskeletal sarcomas

D. Hawkins, 2006 .

Metabolic response as assessed by 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

D. Rodeberg, S. Spunt, D. Hawkins, 2020, Cancer medicine.

Local control for high-grade Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) assigned to radiation therapy on xxx: A report from the xxx.

James R. Anderson, S. Donaldson, D. Rodeberg, 2021, International journal of radiation oncology, biology, physics.

Randomized phase III trial comparing vincristine, actinomycin, cyclophosphamide (VAC) with VAC/V topotecan/cyclophosphamide (TC) for intermediate risk rhabdomyosarcoma (IRRMS). D9803, COG study

D. Rodeberg, J. Stoner, D. Hawkins, 2007 .

Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.

James R. Anderson, D. Rodeberg, S. Spunt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy

J. Meza, S. Donaldson, D. Hawkins, 2017, Pediatric blood & cancer.

Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents

David C. Jones, P. Kearns, X. Paoletti, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing’s sarcoma and alveolar rhabdomyosarcoma

D. Hawkins, B. Thomson, J. Felgenhauer, 1999, Bone Marrow Transplantation.

Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database

E. Erhardt, S. Plon, Heather E. Danysh, 2015, Cancer medicine.

Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children’s Oncology Group

S. Spunt, S. Skapek, D. Hawkins, 2016, Scientific Reports.

Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group

K. Matthay, S. Lessnick, E. Sinclair, 2016, Clinical Cancer Research.

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma

D. Reinke, K. Ballman, D. Hawkins, 2020, Cancer.

Sarcomas gone bad: What to do about recurrent Ewing sarcoma

D. Hawkins, 2011, Pediatric Blood & Cancer.

Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A COG-ALTE03N1 and CCSS report.

M. Relling, G. Armstrong, M. Hudson, 2019, Journal of Clinical Oncology.

Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes.

J. Khan, T. Triche, D. Rakheja, 2018, Cell reports.

A novel algorithm for simplification of complex gene classifiers in cancer.

Stephen X Skapek, Samuel L Volchenboum, Timothy J Triche, 2013, Cancer research.

Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.

T. Triche, E. Davicioni, S. Donaldson, 2011, Journal of Clinical Oncology.

Surgical management of extremity rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, the European Pediatric Soft‐Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe

D. Rodeberg, D. Hawkins, E. Koscielniak, 2020, Pediatric blood & cancer.

Rhabdomyosarcoma in infants younger than 1 year

James R. Anderson, S. Donaldson, D. Rodeberg, 2011, Cancer.

Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.

D. Rodeberg, J. Stoner, D. Hawkins, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Creating a data commons: The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT)

Kirk D. Wyatt, D. Rodeberg, D. Hawkins, 2022, Pediatric blood & cancer.

Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups

James R. Anderson, D. Hawkins, M. Carli, 2015, Pediatric blood & cancer.

The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group.

J. Khan, D. Hawkins, E. Rudzinski, 2020, European journal of cancer.

Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS‐IV in intermediate risk rhabdomyosarcoma: A report from the Children's Oncology Group

James R. Anderson, J. Neglia, D. Hawkins, 2008, Pediatric blood & cancer.

Introducing INSTRuCT: An international effort to promote cooperation and data sharing

D. Hawkins, E. Koscielniak, G. Bisogno, 2020, Pediatric blood & cancer.

An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy

D. Hawkins, G. Bisogno, 2020, Pediatric blood & cancer.

Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children’s Oncology Group, the Children’s Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute.

J. Khan, Jun S. Wei, S. Skapek, 2018 .

Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event‐free survival in intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group

Christine Rimorin, D. Hawkins, J. McCune, 2021, Pediatric blood & cancer.

Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee.

James R. Anderson, S. Donaldson, D. Rodeberg, 2014 .

Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS).

James R. Anderson, J. Michalski, D. Hawkins, 2010 .

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

B. Freidlin, J. Berlin, K. Flaherty, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Vaginal Ewing Sarcoma: An Uncommon Clinical Entity in Pediatric Patients

D. Hawkins, N. Cross, E. Rudzinski, 2017, Journal of Clinical Imaging Science.

Evaluation of Early Marrow Response in Childhood Aneuploid Acute Lymphoblastic Leukemia: Flow Cytometric DNA Analysis versus Standard Morphology

D. Hawkins, J. Rutledge, L. Finn, 2004, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.

James R. Anderson, D. Rodeberg, D. Hawkins, 2014, European journal of cancer.

Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group

E. Erhardt, Heather E. Danysh, S. Skapek, 2014, Cancer Causes & Control.

Randomized phase II window study of two schedules of irinotecan (CPT-11) and vincristine (VCR) in rhabdomyosarcoma (RMS) at first relapse/disease progression

S. Donaldson, C. Paidas, D. Hawkins, 2008 .

Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG Oncology

S. Spunt, D. Hawkins, S. Terezakis, 2023, Journal of surgical oncology.

Clinical Outcomes of Diffuse Sclerosing Variant Papillary Thyroid Carcinoma in Pediatric Patients

D. Hawkins, E. Rudzinski, Yajuan J. Liu, 2021, The Laryngoscope.

Outcomes following preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children's Oncology Group (COG) and NRG Oncology.

Jessica L. Davis, R. Randall, S. Spunt, 2022, Journal of Clinical Oncology.

Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group.

James R. Anderson, S. Donaldson, D. Rodeberg, 2011, International journal of radiation oncology, biology, physics.

INFLUENCE OF NON-COMPLIANCE WITH RADIATION THERAPY PROTOCOL GUIDELINES AND OPERATIVE BED RECURRENCES FOR CHILDREN WITH RHABDOMYOSARCOMA AND MICROSCOPIC RESIDUAL DISEASE: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP

S. Donaldson, D. Rodeberg, J. Michalski, 2015 .

Results of the dose-finding phase of ARST 1321 from the Children's Oncology Group and NRG Oncology: Neoadjuvant chemoradiation or radiation therapy +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcomas.

R. Randall, S. Spunt, D. Hawkins, 2019, Journal of Clinical Oncology.

Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group

D. Hawkins, E. Rudzinski, S. Wolden, 2020, Pediatric blood & cancer.

Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul).

U. Dirksen, I. Judson, D. Hawkins, 2016 .

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Sara M. Federico, M. Kool, G. Vassal, 2023, European journal of cancer.

Minimal residual disease detected prior to hematopoietic cell transplantation

D. Hawkins, M. Loken, D. Wells, 2011, Pediatric blood & cancer.

Children's Oncology Group's 2023 blueprint for research

D. Hawkins, L. Gore, 2023, Pediatric blood & cancer.

Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children’s Oncology Group study ARST0332.

James R. Anderson, R. Randall, F. Laurie, 2014 .

The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.

James R. Anderson, S. Donaldson, J. Michalski, 2013, International journal of radiation oncology, biology, physics.

Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group.

James R. Anderson, S. Donaldson, D. Hawkins, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Desmoid tumours in children: when wait-and-see becomes wait-and-treat.

D. Hawkins, A. Weiss, 2017, The Lancet. Child & adolescent health.

Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I).

T. Alonzo, M. Mooney, D. Hawkins, 2023, Journal of Clinical Oncology.

Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).

T. Alonzo, M. Mooney, D. Hawkins, 2023, Journal of Clinical Oncology.

Tazemetostat for Tumors Harboring SMARCB1/SMARCA4 or EZH2 Alterations: Results from NCI-COG Pediatric MATCH APEC1621C.

N. Ramirez, M. Mooney, D. Hawkins, 2023, Journal of the National Cancer Institute.

Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).

T. Alonzo, M. Mooney, D. Hawkins, 2022, Journal of Clinical Oncology.

ARST1321: Pazopanib neoadjuvant trial in non-rhabdomysarcoma soft tissue sarcomas: A report of major wound complications.

R. Randall, D. Hawkins, Yen-Lin E Chen, 2019, Journal of Clinical Oncology.

K. S. Hall, M. Sydes, P. Leavey, 2016, The Lancet. Oncology.

Identification of novel hypermethylated or hypomethylated CpG sites and genes associated with anthracycline-induced cardiomyopathy

M. Hudson, J. Neglia, D. Hawkins, 2023, Scientific reports.

Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma

M. Marra, A. Mungall, Jessica Halparin, 2018, Cold Spring Harbor molecular case studies.

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Noah E. Berlow, Matthew N. Svalina, T. Perkins, 2019, Skeletal Muscle.

The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer

Allison P. Heath, A. Kerlavage, L. Staudt, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG).

James R. Anderson, D. Rodeberg, D. Hawkins, 2014 .

Outcome of recurrent osteosarcoma patients enrolled in seven phase II trials through CCG, POG, and COG: Learning from the past to move forward.

D. Hawkins, B. Widemann, T. Zwerdling, 2015 .

Ifosfamide and Etoposide Are Superior to Vincristine and Melphalan for Pediatric Metastatic Rhabdomyosarcoma When Administered With Irradiation and Combination Chemotherapy: A Report From the Intergroup Rhabdomyosarcoma Study Group

P. Sorensen, James R. Anderson, T. Triche, 2001, Journal of pediatric hematology/oncology.

Rare Tumors: Opportunities and challenges from the Children's Oncology Group perspective.

D. Hawkins, C. Rodríguez-Galindo, M. Chintagumpala, 2023, EJC paediatric oncology.

Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity

D. Hawkins, B. Thomson, R. Gardner, 2013, Pediatric blood & cancer.

The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols

P. Sorensen, James R. Anderson, T. Triche, 2001, Sarcoma.

Second-look operation with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG).

S. Donaldson, D. Rodeberg, C. Paidas, 2010 .

Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation: Is It Time for a Paradigm Shift?

D. Hawkins, M. Brose, E. Rudzinski, 2020, JAMA otolaryngology-- head & neck surgery.

D. Hawkins, B. Widemann, T. Zwerdling, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline‐Induced Cardiomyopathy – A COG‐ALTE03N1 Report

M. Hudson, J. Neglia, D. Hawkins, 2023, Journal of the American Heart Association.

[F‐18]‐fluorodeoxy‐D‐glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults

J. Eary, E. Conrad, S. Schuetze, 2009, Cancer.

Statistical Considerations in Pediatric Cancer Trials: Report of American Statistical Association Biopharmaceutical Section Open Forum Discussions

Karen L. Price, Olga V. Marchenko, A. Naranjo, 2023, Statistics in Biopharmaceutical Research.

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

M. Sydes, P. Leavey, R. Goldsby, 2019, European journal of cancer.

Sara M. Federico, M. Kool, G. Vassal, 2023, European journal of cancer.